News 15.03.2021 Zurich-Schlieren, Switzerland, March 15, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3...
Events, External events
Event date: 15.03.2021
Challenges at the Interface of Formulation, Primary Packaging and Clinical Administration
As pipelines move to progressively challenging biologics, such as bispecific antibodies, fusion proteins and other complex constructs with little to no prior knowledge, a well-designed drug product is essential for addressing the health authorities' expectations and ensuring clinical success.
Are you...
News 11.03.2021 Zurich-Schlieren, Switzerland, March 10, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the upcoming presentation of four posters with data supporting three of the company’s immunotherapy programs at the American Academy for...
News 09.03.2021 Zurich-Schlieren, Switzerland, March 09, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced initial results from its ongoing phase 1 study of its first tri-specific COVID-19 antiviral treatment, ensovibep (MP0420),...
Events, External events
Event date: 24.03.2021
Date: March 24, 2021
Time: 08.00 am
Duration: 1 hour
After defining what are digital therapeutics (DTx) and how they fit within the broader scope of digital health products, we will look at some examples of this new class of products. Also, we will provide an overview of the current and future market,...